Menu

The HHMI Bump

A new study shows a slight citation benefit to authors recently awarded investigator status from the Howard Hughes Medical Institute.

Jan 28, 2014
Bob Grant

WIKIMEDIA, DVORTYGIRLScientific papers published just prior to their authors being awarded a coveted investigator position at the Howard Hughes Medical Institute (HHMI) are cited 12 percent more than expected, according to new research. The citation bump was more pronounced for papers published in new areas of research or in lower-profile journals. The study, published in this month’s issue of Management Science, compared more than 3,600 life science papers written by 424 HHMI investigators to an equal number of papers written by researchers who had not received the honor. “We found that there was an effect of status,” MIT economist Pierre Azoulay, study coauthor, said in a statement.

Azoulay and his collaborators tracked changes in the citation rates of papers before and after one or more of their authors were named HHMI investigators. They found that citations jumped for some of the papers just after their authors joined the HHMI fold.

“You couldn’t tell them [the pairs of papers] apart in terms of citation trajectories, up until the time of the prize,” Azoulay said.

But the effect was more pronounced in some instances. The citation bump was nearly twice as great for papers published in lower-profile journals, and younger researcher/authors, with less robust reputations prior to their HHMI appointments were more likely to experience the benefits of the award. “The effect was much more pronounced when there was more reason to be uncertain about the quality of the science or the scientist before the prize,” Azoulay added.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.